SMAD2/3 Phosphorylation Motif Mutants in Cancer

Stable Identifier
R-HSA-3304356
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

The conserved phosphorylation motif Ser-Ser-X-Ser at the C-terminus of SMAD2 and SMAD3 is subject to disruptive mutations in cancer. The last two serine residues in this conserved motif, namely Ser465 and Ser467 in SMAD2 and Ser423 and Ser425 in SMAD3, are phosphorylated by the activated TGF beta receptor complex (Macias Silva et al. 1996, Nakao et al. 1997). Once phosphorylated, SMAD2 and SMAD3 form transcriptionally active heterotrimers with SMAD4 (Chacko et al. 2001, Chacko et al. 2004). Phosphorylation motif mutants of SMAD2 and SMAD3 cannot be activated by the TGF-beta receptor complex either because serine residues are substituted with amino acid residues that cannot be phosphorylated or because the phosphorylation motif is deleted from the protein sequence or truncated (Fleming et al. 2013).

Literature References
PubMed ID Title Journal Year
8980228 MADR2 is a substrate of the TGFbeta receptor and its phosphorylation is required for nuclear accumulation and signaling

Macias-Silva, M, Abdollah, S, Hoodless, PA, Pirone, R, Attisano, L, Wrana, JL

Cell 1996
15350224 Structural basis of heteromeric smad protein assembly in TGF-beta signaling

Chacko, BM, Qin, BY, Tiwari, A, Shi, G, Lam, S, Hayward, LJ, De Caestecker, M, Lin, K

Mol Cell 2004
11224571 The L3 loop and C-terminal phosphorylation jointly define Smad protein trimerization

Chacko, BM, Qin, B, Correia, JJ, Lam, SS, de Caestecker, MP, Lin, K

Nat. Struct. Biol. 2001
9346966 Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor-beta signaling

Souchelnytskyi, S, Tamaki, K, Engstrom, U, Wernstedt, C, ten Dijke, P, Heldin, CH

J Biol Chem 1997
23139211 SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer

Fleming, NI, Jorissen, RN, Mouradov, D, Christie, M, Sakthianandeswaren, A, Palmieri, M, Day, F, Li, S, Tsui, C, Lipton, L, Desai, J, Jones, IT, McLaughlin, S, Ward, RL, Hawkins, NJ, Ruszkiewicz, AR, Moore, J, Zhu, HJ, Mariadason, JM, Burgess, AW, Busam, D, Zhao, Q, Strausberg, RL, Gibbs, P, Sieber, OM

Cancer Res. 2013
9311995 TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4

Nakao, A, Souchelnytskyi, S, Kawabata, M, Ishisaki, A, Oeda, E, Tamaki, K, Hanai, J, Heldin, CH, Miyazono, K, ten Dijke, P

EMBO J 1997
Participants
Participant Of
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Cross References
Authored
Reviewed
Created